LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen.

Authors :: Lee, S.M.
Schulz, C.
Prabhash, K.
Han, B.
Szczesna, A.
Cortinovis, D.L.
Rittmeyer, A.
Baz, D. Vicente
Califano, R.
Anh, L. Tuan
Liu, G.
Cappuzzo, F.
Contreras, J.G. Reyes
Reck, M.
Hu, Y.
Morris, S.
Hoeglander, E.K.
Connors, M.
Vollan, H.K.M.
Peters, S.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1418-S1419. 2p.
Publication Year :: 2022

Subjects :: *ATEZOLIZUMAB
*NON-small-cell lung carcinoma
*CANCER chemotherapy
*PATIENTS

Full Text Access

Tools